Calendario›CGC›Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity
Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity
Ensayo de Canopy Growth Corp en Delayed Onset Muscle Soreness (DOMS) (del registro, en inglés).
- Fase
- Fase 2
- Estado
- Completado
- Participantes
- 40
- Centros
- 1
- Fin del objetivo primario
- feb 2022
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, triple ciego. Comenzó en dic 2021.
Qué mide
Changes from baseline in blood pressure (mmHg) [Safety and Tolerability] (del registro, en inglés) (dia 2)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe study is designed as a proof of concept, single-center, randomized, double-blind, placebo controlled study to assess the safety and efficacy of CHI-202 (cannabinoids and other ingredients) compared to placebo in the treatment of Delayed Onset Muscle Soreness (DOMS).
Más ensayos de CGC
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Canadian Registry for the Use of Spectrum Therapeutics Cannabis Products in Subjects With Chronic Pain | no aplica | Sin noticias del promotor | jul 2023 (prevista, ya pasada: sin actualizar en el registro) |
| A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on Sleep Quality | Fase 1/2 | Completado | dic 2022 (real) |
| CBD | Fase 1 | Interrumpido | sep 2022 (real) |
| Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants | Fase 1 | Completado | may 2022 (real) |
| Cannabidiol | Fase 2 | Completado | sep 2021 (real) |
| CHI-907 CBD Extract and Experiences of Test Anxiety | Fase 2 | Interrumpido | jun 2021 (real) |
Todos los de CGC, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT05026164), actualizada en feb 2022.